ReviewSmall science2026
Remodeling the Inflammatory Microenvironment: Nanomaterial-Based Targeted Strategies for Systemic Lupus Erythematosus and Lupus Nephritis.
Review in Small science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic Lupus Erythematosus (SLE) is a complex autoimmune disorder, with Lupus Nephritis (LN) representing a severe complication that affects a significant proportion of patients. Current treatments, including corticosteroids and immunosuppressants, are limited by systemic toxicity and nonspecific biodistribution. Nanomaterial-based drug delivery systems have emerged as a promising strategy to overcome these challenges by improving drug solubility, facilitating targeted delivery, and reducing off-target effects. This review comprehensively discusses the rational design and application of advanced nanomaterials-such as liposomes, polymeric nanoparticles, dendrimers, and biomimetic nanocarriers-in the context of SLE/LN therapy. It highlights how tailored nanoplatforms can selectively target key immune cells (e.g., T cells, B cells, macrophages, and dendritic cells) and renal parenchymal cells, support combination therapy, and improve therapeutic outcomes while minimizing off-target effects. Furthermore, the review critically examines current challenges and future prospects for clinical translation, advocating for smarter nano-therapeutics capable of integrating immune modulation and organ-specific targeting. This work aims to bridge materials design and immunology, providing insights into next-generation treatments for SLE/LN diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.